Government Administration - Lausanne, Vaud, Switzerland
(a) Monitor and reduce the non-adherence rate of drug-clinical-trials in Phase III and Phase IV(b) Improve patient treatment compliance at home avoiding trial readmission cost due to non-adherence(c) Optimize home drug delivery to patient and real-time follow-up